Tyrosine Kinase Inhibitors: all 10,469 studies that test it
Page 11 of 105. Open to participants first (1,907), then studies with results posted, then the rest; newest registration first within each.
- Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCLEnrolling by invitationNCT06468943Phase 2
- Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKiRecruitingNCT06466122Phase 2
- Efficacy and Safety of Dupilumab in Combination With Tofacitinib in Moderate to Severe Adult AD PatientsNot yet recruitingNCT06465732Phase 4
- Adebrelimab in Combination With Apatinib and Chemotherapy/Chemoradiotherapy in Immuno-experienced Second-line ESCC.Not yet recruitingNCT06464614Phase 2
- Sonrotoclax, Zanubrutinib and CD20mab in Untreated MCL PatientsRecruitingNCT06463691Phase 2
- Irinotecan Hydrochloride Liposome Combined With Capecitabine and Lenvatinib in Patients With Biliary Tract CarcinomaNot yet recruitingNCT06463548Not applicable
- Study of SGR-3515 In Participants With Advanced Solid Tumors.RecruitingNCT06463340Phase 1
- Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung CancerNot yet recruitingNCT06463171Phase 2
- Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLCNot yet recruitingNCT06456138Phase 1/2
- Cadonilimab Combined With Regorafenib as A Third-line Treatment in Patients With MSS CRLMRecruitingNCT06455254Phase 2
- Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.RecruitingNCT06454968Phase 2
- Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative ResectionRecruitingNCT06454578Phase 2
- Efficacy of Upadacitinib After NECS in VitiligoRecruitingNCT06454461Not applicable
- A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic ArthritisRecruitingNCT06454188Phase 4
- TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) PatientsRecruitingNCT06453902Phase 2
- Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.Not yet recruitingNCT06452433Phase 2
- A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)RecruitingNCT06452277Phase 3
- A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacokinetic of TQB3702 Tablets in Healthy Adult SubjectsRecruitingNCT06448273Phase 1
- Fruquintinib After ICIs Treatment in Unresectable Hepatocellular CarcinomaRecruitingNCT06446154Phase 2
- A Clinical Study Evaluating the Safety and Efficacy of ZRMT Regimen in the Treatment of PCNSLRecruitingNCT06445257Not applicable
- Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small CellNot yet recruitingNCT06441344Phase 3
- Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCLNot yet recruitingNCT06441097Phase 2
- The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast CancerRecruitingNCT06439693Phase 2
- Baricitinib for the Lung Injury Following Spontaneous SAHNot yet recruitingNCT06439615Phase 2
- Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 FusionRecruitingNCT06439485Phase 1/2
- 3T Therapy in the Treatment of MDA5-positive DermatomyositisEnrolling by invitationNCT06438679Phase 4
- An Exploratory Study of Efficacy and Safety of Iruplinalkib Tablets in Patients With ROS1 Positive Non-small Cell Lung CancerRecruitingNCT06436885Early Phase 1
- Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLCNot yet recruitingNCT06436144Phase 2
- A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.RecruitingNCT06434597Phase 2
- Anlotinib Combined With Benmelstobart for Advanced PheochromocytomaNot yet recruitingNCT06429397Phase 2
- A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)RecruitingNCT06428019Phase 3
- This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell LymphomaNot yet recruitingNCT06427213Phase 2
- Neoadjuvant Cadonilimab Combined With Anlotinib in Locally Advanced Resectable Esophageal Squamous Cell CarcinomaNot yet recruitingNCT06426797Phase 2
- Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal CancersRecruitingNCT06425133Phase 2
- A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal MelanomaEnrolling by invitationNCT06424626Phase 1
- Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal CancerNot yet recruitingNCT06423937Phase 2
- Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning ModelRecruitingNCT06420440Phase 2
- Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain MetastasisRecruitingNCT06418594Phase 2
- Lenvatinib and Adebrelimab Combined With GEMOX in the Perioperative Treatment of Potentially Resectable Intrahepatic CholangiocarcinomaNot yet recruitingNCT06417606Phase 4
- A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction AdenocarcinomaRecruitingNCT06415669Phase 2
- Surufatinib Combined With Tislelizumab in Advanced Lung Cancer With Neuroendocrine DifferentiationNot yet recruitingNCT06414915Phase 2
- Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or DeclinedRecruitingNCT06414681Early Phase 1
- PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CMLRecruitingNCT06409936Phase 2
- FOLFOX Plus Lenvatinib Adjuvant Therapy for Hepatocellular Carcinoma Post-Liver TransplantationNot yet recruitingNCT06409637Phase 1/2
- A Phase II Clinical Study of Cadonilimab in Treatment-naïve or Relapsed Extensive Small Cell Lung CancerRecruitingNCT06406673Phase 2
- Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular CarcinomaRecruitingNCT06406634Phase 2
- A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid LeukemiaRecruitingNCT06401603Phase 1
- A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian CancerRecruitingNCT06394804Phase 2
- High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With OsimertinibRecruitingNCT06394674Phase 2
- Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)RecruitingNCT06390956Phase 2
- Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)RecruitingNCT06390319Phase 2
- A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)RecruitingNCT06389799Phase 2
- HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract CancerNot yet recruitingNCT06389500Phase 2
- TSN084 Treating Patients With Advanced Malignant TumorsRecruitingNCT06386705Phase 1
- Neoadjuvant Targeted Therapy in Patients With Resectable EGFR-mutated Lung Squamous Cell CarcinomaRecruitingNCT06383728Phase 2
- Safety and Efficacy of XELOX Combined With Sintilimab and Lenvatinib in Advanced AFP-positive Gastric Cancer PatientsRecruitingNCT06383559Phase 2
- Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket TrialRecruitingNCT06381661Phase 2
- JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins MutationsNot yet recruitingNCT06380348Phase 3
- Drug-Drug Interaction (DDI) Study of Leramistat in Healthy Adult SubjectsRecruitingNCT06379958Phase 1
- Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLCRecruitingNCT06379087Phase 2
- A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on LorlatinibRecruitingNCT06378892Phase 2
- A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 AlterationsRecruitingNCT06378593Phase 1/2
- Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid CancerRecruitingNCT06374602Phase 2
- Ritlecitinib in Patients With Keloids or Those Undergoing KeloidectomyRecruitingNCT06373458Phase 2
- Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal CancerRecruitingNCT06369259Phase 2
- Azenosertib in Uterine Serous Carcinoma: Biomarker StudyRecruitingNCT06369155Phase 2
- A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid LeukemiaRecruitingNCT06368414Phase 2
- MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLLNot yet recruitingNCT06367374Phase 2
- Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid LeukemiaRecruitingNCT06366789Phase 1
- CARE1 Pragmatic Clinical TrialRecruitingNCT06364631Phase 3
- Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid TumorsRecruitingNCT06364410Phase 1
- A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCLRecruitingNCT06363994Phase 3
- Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II TrialRecruitingNCT06363734Phase 2
- A Study of SC-0191 in Subjects With Metastatic Colorectal CancerNot yet recruitingNCT06363552Phase 2
- Toripalimab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract CancerRecruitingNCT06362317Phase 2
- A Study to Evaluate Safety, Tolerability and Pharmacokinetic of ND-003 Tablets in Healthy AdultsEnrolling by invitationNCT06360874Phase 1
- Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCCRecruitingNCT06360042Phase 2
- Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL TrialRecruitingNCT06357676Phase 1/2
- A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With Advanced NSCLC With Driver-negative After Progression to ImmunotherapyNot yet recruitingNCT06356675Phase 4
- Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast CancerRecruitingNCT06355037Phase 2
- A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT06354530Phase 2/3
- A Study to Evaluate the Mass Balance of [14C] SY-5007 in Healthy Adult Male Subjects in ChinaNot yet recruitingNCT06352190Phase 1
- To Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsule in Postoperative Non-pCR Patients With Non-small Cell Lung CancerRecruitingNCT06352008Phase 2
- Rituximab and Zanubrutinib in Patients With Indolent B-cell LymphomasRecruitingNCT06350318Phase 2
- High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With SplenomegalyRecruitingNCT06345495Phase 2
- Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKIRecruitingNCT06343064Phase 1/2
- A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell LymphomaRecruitingNCT06341556Phase 2
- Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune Rechallenge Therapy in Esophageal Squamous Cell CarcinomaRecruitingNCT06339619Phase 2
- A Multicenter Clinical Study of Apatinib Mesylate Combined With Doctor's Choice for Advanced Breast CancerNot yet recruitingNCT06339281Phase 2
- A Study of Furmonertinib Combined With Chemotherapy in the Treatment of NSCLC With Leptomeningeal MetastasisRecruitingNCT06339242Phase 2
- A Clinical Study of Adebrelimab Combined With Apatinib and Paclitaxel in Patients With Advanced Gastric Cancer.Not yet recruitingNCT06339216Phase 2
- Adibelimab, Famitinib and Chemotherapy for Advanced NSCLC After PD-1 Inhibitor FailureNot yet recruitingNCT06336954Phase 2
- Ma-Spore ALL 2020 StudyRecruitingNCT06336395Phase 2
- Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK FusionRecruitingNCT06333899Early Phase 1
- Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic LeukemiaRecruitingNCT06333262Phase 2
- Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With ImmunotherapyNot yet recruitingNCT06332950Phase 1/2
- A Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of SY-5007 in Healthy SubjectsNot yet recruitingNCT06332053Phase 1
- Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast CancerRecruitingNCT06331169Phase 1
- A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRADNot yet recruitingNCT06329947Phase 2
- Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy FailureNot yet recruitingNCT06327698Phase 2